Drug profile · INN
fam-trastuzumab deruxtecan-nxki
ENHERTU
fam-trastuzumab deruxtecan-nxki (ENHERTU) is a dna topoisomerase i inhibitor. Route of administration: injection. Current US regulatory status: approved.
Drug details — fam-trastuzumab deruxtecan-nxki
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
fam-trastuzumab deruxtecan-nxki (ENHERTU) is a dna topoisomerase i inhibitor. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
DNA topoisomerase I inhibitor
Primary target: DNA topoisomerase 1
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Recent coverage
Enhertu's Dual FDA Approvals: A Game Changer in Early Breast Cancer Treatment
Daiichi and AstraZeneca's Enhertu has received dual FDA approvals for early breast cancer, marking a significant milestone in oncology. This article explores the implications for investors and pharma teams.
Novo Nordisk Launches Wegovy in China Before Eli Lilly, Capturing World's Largest Obesity Market
Novo Nordisk secures first-mover advantage launching Wegovy in China ahead of Eli Lilly's competing obesity drug, targeting massive untapped market opportunity.
Related & competitor drugs
Frequently asked questions
What is fam-trastuzumab deruxtecan-nxki?
fam-trastuzumab deruxtecan-nxki (ENHERTU) is a dna topoisomerase i inhibitor. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for fam-trastuzumab deruxtecan-nxki?
ENHERTU is a marketed brand name for fam-trastuzumab deruxtecan-nxki. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of fam-trastuzumab deruxtecan-nxki?
fam-trastuzumab deruxtecan-nxki has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.